Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.
Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.